Inogen (INGN) to Release Quarterly Earnings on Tuesday

Inogen (NASDAQ:INGN) will likely be releasing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Inogen to post earnings of ($0.36) per share and revenue of $82.00 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Inogen Price Performance

Shares of NASDAQ INGN opened at $5.76 on Tuesday. Inogen has a 1-year low of $5.48 and a 1-year high of $11.94. The business has a fifty day moving average price of $6.40 and a 200 day moving average price of $7.29. The stock has a market capitalization of $156.38 million, a P/E ratio of -5.70 and a beta of 1.79.

Institutional Investors Weigh In On Inogen

A number of institutional investors and hedge funds have recently modified their holdings of INGN. Deutsche Bank AG purchased a new stake in Inogen in the fourth quarter valued at $115,000. Brevan Howard Capital Management LP acquired a new position in shares of Inogen in the 3rd quarter valued at about $198,000. Algert Global LLC boosted its stake in shares of Inogen by 22.8% in the third quarter. Algert Global LLC now owns 21,100 shares of the medical technology company’s stock worth $172,000 after buying an additional 3,920 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Inogen by 18.9% during the third quarter. Russell Investments Group Ltd. now owns 17,056 shares of the medical technology company’s stock worth $139,000 after acquiring an additional 2,717 shares during the period. Finally, State of Wyoming grew its holdings in Inogen by 103.9% during the second quarter. State of Wyoming now owns 32,587 shares of the medical technology company’s stock worth $229,000 after acquiring an additional 16,602 shares during the period. Institutional investors and hedge funds own 89.94% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Inogen in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $11.00.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.